BioSpace News Archive

Strata Oncology, Inc. today announced that Gilead Sciences, Inc. has agreed to collaborate on the Strata Precision Indications for Approved THerapies (Strata PATH™) trial by providing TRODELVY® (Sacituzumab govitecan-hziy) for eligible patients with cancer.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) today announced positive results of preclinical studies examining rencofilstat as a potential therapeutic for multiple myeloma (“MM”).

Cytovale® announced today that its IntelliSep® test has received U.S. Food and Drug Administration (FDA) 510(k) clearance to aid in the early detection of sepsis for the approximately 30 million adult patients with signs and symptoms of infection who present to US emergency departments (ED) each year.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX) today announced that it will utilize leading pain expert, Dr. Neil K. Singla, to assist in the design and support of the clinical development strategy for Probudur.

VisualDx, an award-winning web-based clinical decision support system, has received a grant from the Bill & Melinda Gates Foundation to develop diagnostic and surveillance tools to help medical providers improve treatment decisions and outcomes in underserved areas.

Hong Kong Science and Technology Parks (HKSTP) announced a strategic collaboration with Roche, one of the world’s largest pharmaceutical companies, with the aim of leading HK and the Greater Bay Area in becoming a pioneer in life science innovation and to be an example for the region.

The vagus nerve runs from the human brainstem to major peripheral organs and acts as the main conduit for the body’s inflammatory immune response to disease, bacteria and viruses.

Prostate cancer continues to be one of the most common cancers among men nationwide, showing a 3% increase in incidence per year and a 5% increase in advanced-stage diagnoses per year since 2014, a new report shows.

Vetter, a globally leading contract development and manufacturing organization (CDMO), achieved gold status in the renowned, independent EcoVadis sustainability ranking. With 72 points out of a maximum of 100, the pharmaceutical service provider significantly increased its score compared to the last evaluation and is now among the top five percent of all participating companies in the industry.

Medigene AG announced that it has received a $3 million milestone payment from its partner 2seventy bio as part of its T cell receptor agreement in cancer immunotherapy, and which may lead to further potential milestone payments in the future.